-
NMPA Seeks Public Input on Drug Trial Data Protection Measures
•
On March 19, 2025, China’s National Medical Products Administration (NMPA) released draft measures and procedures for drug trial data protection, soliciting public opinions until May 18, 2025. The initiative aims to foster drug innovation and meet public medication needs, in line with relevant pharmaceutical regulations. Data Protection FrameworkThe draft measures…
-
AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio
•
On March 17, 2025, EsoBiotec SA announced a definitive acquisition agreement with AstraZeneca (NASDAQ: AZN). Under the terms of the agreement, AstraZeneca will acquire all outstanding shares of EsoBiotec in a cash and debt-free transaction valued at up to $1 billion. This includes an initial payment of $425 million at…
-
Merck Sharp & Dohme Expands Durham Facility with $1B Investment for Vaccine Production
•
US-based giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the opening of a 225,000 sq. ft. extension to its manufacturing facility in Durham, North Carolina. The expansion, which has received a USD1 billion investment, will focus on vaccine manufacturing and is a key part of MSD’s ongoing commitment…
-
InventisBio Announces Positive Phase II Results for D-2570 in Psoriasis Treatment
•
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) announced positive results from the Phase II study for its oral TYK2 inhibitor D-2570 in psoriasis at the American Academy of Dermatology Annual Meeting (AAD). The data demonstrated significant improvements in patients treated with D-2570 compared to the placebo group. Study ResultsAfter 12…
-
Roche and JD Healthcare Collaborate on Influenza Prevention with Xofluza (Baloxavir Marboxil)
•
Swiss giant Roche’s (SWX: ROG, OTCMKTS: RHHBY) China unit has entered into a collaboration agreement with JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD). This partnership aims to enhance the prevention and control of influenza in China through the innovative “medicine+Internet medicine” model, making Xofluza (baloxavir marboxil)…
-
Organon’s 2024 Financial Report Shows Steady Growth in Women’s Health and Biosimilars
•
Women’s health specialist Organon (NYSE: OGN) released its 2024 financial report, showing a 3% year-on-year (YOY) increase in revenues, excluding foreign exchange effects, to USD 6.4 billion. Global PerformanceGlobally, Women’s Health revenues rose 5% YOY to USD 1.78 billion, primarily driven by a 17% growth in Nexplanon (etonogestrel implant) sales,…
-
Fosun Pharmaceutical’s XS-03 Gets NMPA Green Light for CRC Study
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its Category 1 chemical drug XS-03. The study will assess the drug’s use in combination with FOLFOX or FOLFIRI plus…
-
AstraZeneca’s 2024 Financials Beat Expectations with 21% Revenue Growth
•
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) reported total revenues of USD 54.07 billion in its 2024 financial report, marking a 21% year-on-year (YOY) increase in constant exchange rate terms. Product sales reached USD 50.98 billion, up 19% YOY, with Q4 product sales climbing 19% to USD 13.36 billion. The…
-
Beijing Biostar’s Utidelone Gains FDA Approval for Global Phase II/III Study
•
China’s Beijing Biostar Technologies Ltd (HKG: 2563) announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a global multi-center Phase II/III regulatory study, dubbed BG02-2404. The study will evaluate utidelone in combination with capecitabine and oxaliplatin as a first-line treatment for PD-L1 negative…
-
China’s MoC Lists US Firms PVH and Illumina as Unreliable Entities
•
China’s Ministry of Commerce (MoC) has released a list of unreliable entities, including US firms Philips-Van-Heusen (PVH) and Illumina, Inc. (NASDAQ: ILMN). These companies were cited for violating normal market trading principles, interrupting normal transactions with Chinese enterprises, taking discriminatory measures against Chinese firms, and seriously damaging the legitimate rights…
-
Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion
•
US-based Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks with compatriot firm Scorpion Therapeutics, with the aim of acquiring the oncology biotech for a potential USD 2.5 billion. This strategic move is expected to significantly expand Eli Lilly’s presence in the oncology sector. Deal Details and TimelineAccording…
-
Fujian Cosunter’s COVID-19 Therapy GST-HG171/ritonavir Approved in Macau
•
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that its Category 1 product, GST-HG171/ritonavir, an oral COVID-19 therapy, has been approved for marketing in Macau. This approval expands the availability of the treatment to patients in the region. Previous NMPA ApprovalThe product previously received conditional approval from the…
-
Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co. Launch Strategic Partnership for Linagliptin
•
On January 7, Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) held a strategic cooperation launch ceremony, announcing a partnership on the national retail market for Outangning® (Linagliptin). Starting from January 1, 2025, the distribution and promotion of Linagliptin in non – medical institution…
-
Biogen Gains FDA Breakthrough Status for Felzartamab in Kidney Transplant Rejection Treatment
•
Biogen Inc. (NASDAQ: BIIB) has secured breakthrough therapy designation (BTD) from the U.S. Food and Drug Administration (FDA) for felzartamab, an investigational anti-CD38 monoclonal antibody aimed at treating late antibody-mediated rejection (AMR) without T-cell mediated rejection in kidney transplant patients. This designation is pivotal as AMR is a leading cause…
-
Johnson & Johnson’s Xarelto Demonstrates Reduced Bleeding Risk in Atrial Fibrillation Patients Post-PCI
•
Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced positive results from a Phase III trial, highlighting the efficacy of its anticoagulant Xarelto (rivaroxaban) in reducing the risk of clinically significant bleeding (CSB) and net adverse clinical events (NACE) or rehospitalization in adult patients with nonvalvular atrial fibrillation (AF)…
-
Hengrui Pharmaceuticals Advances Clinical Trial for PD-L1 Inhibitor Combo in CLDN18.2 Positive Tumors
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company, has received approval from China’s National Medical Products Administration (NMPA) to initiate a Phase Ib/III clinical study. The study will evaluate the combination of Hengrui’s PD-L1 monoclonal antibody, adebrelimab (SHR-1316), with the antibody-drug conjugate (ADC) SHR-A1904 in patients with…
-
Celltrion’s Infliximab Biosimilar Shows Promising Long-Term Efficacy and Safety in CD and UC
•
South Korean biopharmaceutical company Celltrion (KRX: 068270) has presented positive long-term efficacy and safety data for its infliximab biosimilar in the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). The biosimilar offers the advantage of subcutaneous administration, providing a more convenient alternative to Johnson & Johnson’s (J&J; NYSE: JNJ)…
-
Blue Sail Medical Secures RMB 900 Million Investment for R&D and Capacity Expansion
•
Blue Sail Medical Co., Ltd (SHE: 002382) has announced that its wholly owned subsidiary, Blue Sail Biosensors Medical Technology, has secured strategic investments totaling RMB 900 million from Capital Health Industry (Beijing) Fund and two other investors. The funds will be allocated to enhance product research and development as well…
-
Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment
•
US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd., (SHE: 000963) regarding their joint development of the type 2 diabetes drug TTP273. Huadong, confirming the cancellation, stated that TTP273 was found to be inferior to its own drug candidate, HDM1002. TTP273, a first-in-class, non-peptide,…
-
Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study
•
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US Food and Drug Administration (FDA) to initiate a Phase I clinical study for HLX42, an antibody drug conjugate (ADC) co-developed with Shanghai Henlius Biotech Inc. (HKG: 2696) and Suzhou-based Medilink Therapeutics. The study targets advanced/metastatic…
